MYCN oncogene
Pronunciation: MY-sin ON-koh-jeen
A proto-oncogene whose amplification is a critical prognostic marker in neuroblastoma, associated with aggressive tumor behavior and poor outcomes.
Full Definition
MYCN (also known as N-MYC) is a member of the MYC family of transcription factors that plays a crucial role in cell proliferation, differentiation, and apoptosis during normal development. In neuroblastoma, amplification of the MYCN gene (defined as >10 copies per cell) occurs in approximately 20% of cases and is strongly associated with advanced stage disease, rapid tumor progression, and poor prognosis regardless of patient age. MYCN amplification is incorporated into all major neuroblastoma risk stratification systems and influences treatment intensity decisions. The presence of MYCN amplification typically classifies patients into high-risk categories requiring intensive multimodal therapy including high-dose chemotherapy with autologous stem cell rescue.
Usage
Usage note: Distinguish from MYCN amplification (the genomic alteration) when referring to the normal gene function.
In Context
- "Fluorescence in situ hybridization revealed MYCN oncogene amplification with a ratio of 15:1." — Molecular genetics report
- "The absence of MYCN oncogene amplification supported assignment to the intermediate-risk treatment protocol." — Clinical trial enrollment documentation